TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB

SIMPLE SUMMARY: Bladder cancer (BCa) is considered one of the most common neoplasms of the urology system. Cisplatin-based chemotherapy has been the primary treatment for patients with advanced or metastatic BCa. Nevertheless, cisplatin resistance often limits the treatment of bladder cancer. We exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Ji, Chen, Wu, Chen, Kang, Zhu, Shaoming, Lin, Fangyou, Qi, Yucheng, Zhang, Yunlong, Han, Shangting, Rao, Ting, Ruan, Yuan, Zhao, Sheng, Yu, Weimin, Cheng, Fan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562889/
https://www.ncbi.nlm.nih.gov/pubmed/36230734
http://dx.doi.org/10.3390/cancers14194809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562889/
https://www.ncbi.nlm.nih.gov/pubmed/36230734
http://dx.doi.org/10.3390/cancers14194809

Ejemplares similares